Pfizer and Valneva Lyme Vaccine Shows Over 70% Efficacy in Phase 3 Trial — But Misses Main Goal

Pfizer and Valneva reported their Lyme disease vaccine demonstrated 73.2% efficacy in the Phase 3 VALOR trial. While it missed the primary statistical target due to fewer cases, strong results support upcoming regulatory submissions.